> Disorders > Disease or Syndrome > Left Ventricular Diastolic Dysfunction

Left Ventricular Diastolic Dysfunction

Q: What are the different types of Left Ventricular Diastolic Dysfunction?

There are several variations of LVDD, including impaired relaxation, pseudonormal filling, and restrictive filling patterns. Each type is characterized by specific changes in the heart's diastolic function and can have different underlying causes and treatment approaches.

Discover how PubCompare.ai optimizes your research on Left Ventricular Diastolic Dysfunction.
Our AI-driven platform helps you locate the best protocols from literature, pre-prinks, and patents, while using intelligent comparisons to enhance reproducibility and accuarcy.
Leverage the power of AI to streamline your research and uncover the most effective solutions.

Most cited protocols related to «Left Ventricular Diastolic Dysfunction»

MESA Cardiovascular Event Adjudication Protocol

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008

Angina Pectoris Asymptomatic Diseases Biological Markers Blood Vessel Brain Brain Metastases Cardiovascular System Cerebral Ventriculography Cerebrovascular Accident Chest Pain Clinical Reasoning Compassion Fatigue Congenital Abnormality Coronary Artery Disease Coronary Occlusion Diagnosis Dyspnea Echocardiography Edema Exercise Tests Heart Heart Ventricle Hospitalization Infection Interviewers Left Ventricular Diastolic Dysfunction Myocardial Infarction Myocardial Ischemia Neoplasms Outpatients Patients Physical Examination Physicians Pulmonary Edema Radiography, Thoracic Traumatic Brain Injury Wounds and Injuries

Cardiac Staging in Aortic Valve Disease

Patients were categorized into five stages (independent, not additive) depending on the presence or absence of extravalvular (extra aortic valve) cardiac damage or dysfunction as detected by transthoracic echocardiography before AVR—Stage 0: No other cardiac damage detected; Stage 1: LV damage as defined by presence of LV hypertrophy (LV mass index >95 g/m² for women, >115 g/m² for men),⁵ (link) severe LV diastolic dysfunction (E/e′ > 14),⁶ (link) or LV systolic dysfunction (LV ejection fraction <50%); Stage 2: LA or mitral valve damage or dysfunction as defined by the presence of an enlarged left atrium (>34 mL/m²), the presence of atrial fibrillation, or the presence of moderate or severe mitral regurgitation; Stage 3: Pulmonary artery vasculature or tricuspid valve damage or dysfunction as defined by the presence of systolic pulmonary hypertension (systolic pulmonary arterial pressure ≥60 mmHg) or the presence of moderate or severe tricuspid regurgitation⁷ (link)^,⁸ (link); and Stage 4: RV damage as defined by the presence of moderate or severe RV dysfunction (Figure 1).⁵ (link)^,⁶ (link)^,⁹ (link)^,¹⁰ (link) Patients were hierarchically classified in a given stage (worst stage) if at least one of the proposed criteria was met within that stage. These criteria were chosen based on their broad acceptance, prior validation as markers of abnormal cardiac function, their simplicity of acquisition, and their potential for future clinical external generalizability.¹ (link)^,² (link)^,⁵ (link)^,⁶ (link) The classification algorithm as well as the statistical models were defined fully a priori. Frailty was defined as the presence of at least two of the following criteria: (i) Katz index of independence in activities of daily living <6; (ii) 15-m walk time ≥24 s, (iii) serum albumin <3.8 g/dL, and (iv) grip strength <13 kg (women) or <26 kg (men).¹¹ (link)
Transthoracic echocardiograms were obtained at baseline and follow-up using a uniform image acquisition protocol. All studies were analysed by a central core laboratory with quality and measurement methodology previously reported.¹² (link)^,¹³ (link) All adverse events were adjudicated by an independent committee.

Généreux P., Pibarot P., Redfors B., Mack M.J., Makkar R.R., Jaber W.A., Svensson L.G., Kapadia S., Tuzcu E.M., Thourani V.H., Babaliaros V., Herrmann H.C., Szeto W.Y., Cohen D.J., Lindman B.R., McAndrew T., Alu M.C., Douglas P.S., Hahn R.T., Kodali S.K., Smith C.R., Miller D.C., Webb J.G, & Leon M.B. (2017). Staging classification of aortic stenosis based on the extent of cardiac damage. European Heart Journal, 38(45), 3351-3358.

Publication 2017

Atrial Fibrillation Atrium, Left BAD protein, human Echocardiography Heart Left Ventricular Diastolic Dysfunction Left Ventricular Hypertrophy Left Ventricular Systolic Dysfunction Lung Mitral Valve Mitral Valve Insufficiency Patients Pulmonary Artery Pulmonary Hypertension Serum Albumin Systole Systolic Hypertension Systolic Pressure Valves, Aortic Valves, Tricuspid Woman

Diagnosing Congestive Heart Failure

Median follow-up time was 4.0 years (interquartile range, 3.1-4.2 years), which resulted in 25 107 person-years of observation. A telephone interviewer contacted each participant every 6 to 9 months to inquire about all interim hospital admissions, cardiovascular outpatient diagnoses, and deaths. Two physicians reviewed each record for independent endpoint classification and assignment of event dates.
The endpoint for this study was symptomatic CHF. End point criteria were (a) CHF diagnosed by a physician and patient receiving medical treatment for CHF; (b) pulmonary edema/congestion seen on a chest radiograph; and (c) dilated ventricle or poor LV systolic function by echocardiography or ventriculography, or evidence of LV diastolic dysfunction by echocardiography. Participants who met only criterion a were considered to meet a “soft” criterion, and participants who met criteria b and c in addition to a physician diagnosis were classified as meeting “hard” criteria for CHF. For this analysis, participants who met either soft or hard criteria were considered as having incident CHF. An MI was diagnosed based on standard criteria consisting of combinations of symptoms, ECG findings, and cardiac biomarker levels.24 (link)

Bahrami H., Kronmal R., Bluemke D.A., Olson J., Shea S., Liu K., Burke G.L, & Lima J.A. (2008). Differences in the Incidence of Congestive Heart Failure by Ethnicity: The Multi-Ethnic Study of Atherosclerosis. Archives of internal medicine, 168(19), 2138-2145.

Publication 2008

Biological Markers Cardiovascular System Cerebral Ventriculography Echocardiography Heart Heart Ventricle Interviewers Left Ventricular Diastolic Dysfunction Outpatients Patients Physicians Pulmonary Edema Radiography, Thoracic Systole Vision

Hospitalized Heart Failure Adjudication in WHI

Incident hospitalized HF was ascertained yearly in WHI by medical record abstraction of self-report hospitalizations and classified by trained adjudicators using the standardized methodology as previously described.^{18 (link)} Hospitalized HF requiring and/or occurring during hospitalization required physician diagnosis of new-onset or worsened congestive HF on the reported hospital admission and 1 or more of the following 4 criteria: HF diagnosed by physician and receiving medical treatment for HF, symptoms plus documentation in the current medical record of a history of an imaging procedure showing impaired left ventricular (LV) systolic or diastolic LV function, pulmonary edema/congestion on chest x-ray on the current admission, dilated ventricle(s) or “poor” LV or right ventricular (RV) function by echocardiography, radionuclide ventriculography, or other contrast ventriculography, or evidence of LV diastolic dysfunction. This method was found to have an excellent 79% agreement rate (kappa) comparing central adjudicated HF to local adjudication.^{18 (link)}Interim CHD was defined by adjudicated hospitalization for myocardial infarction, PTCA, CABG, or angina after baseline and prior to the HF hospitalization.^{18 (link)}

Eaton C.B., Abdulbaki A.M., Margolis K.L., Manson J.E., Limacher M., Klein L., Allison M.A., Robinson J.G., Curb J.D., Martin L.A., Liu S, & Howard B.V. (2012). Racial and Ethnic Differences in Incident Hospitalized Heart Failure in Post Menopausal Women: The Women’s Health Initiative. Circulation, 126(6), 688-696.

Publication 2012

Angina Pectoris Cerebral Ventriculography Coronary Artery Bypass Surgery Diastole Echocardiography Heart Ventricle Hospitalization Left Ventricles Left Ventricular Diastolic Dysfunction Left Ventricular Function Medical Imaging Myocardial Infarction Percutaneous Transluminal Coronary Angioplasty Physicians Pulmonary Edema Radiography, Thoracic Radionuclide Ventriculography Systole Ventricular Function, Right

Longitudinal Surveillance of Cardiovascular Events

Participants were re-examined approximately every other year after the baseline examination.^{13 (link)} In addition to the study examinations, a telephone interviewer contacted each participant every 9–12 months to inquire about all interim hospital admissions, cardiovascular outpatient diagnoses and deaths. To verify self-reported diagnoses, copies were requested of all death certificates and medical records for all hospitalisations and outpatient cardiovascular diagnoses. Next-of-kin interviews for out-of-hospital cardiovascular deaths were obtained. We were successful in getting medical records on an estimated 98% of hospitalised cardiovascular events and information on 95% of outpatient cardiovascular diagnostic encounters. Follow-up telephone interviews were completed by 92% of living participants.^{12 (link)} Trained personnel abstracted any hospital records suggesting possible cardiovascular events and transmitted these to the coordinating centre. These were then sent to two paired physicians (cardiologists or cardiovascular physician epidemiologists) for independent end point classification and assignment of incidence dates. Persisting disagreements were classified by the full review committee. The end point for this study was a composite of probable and definite HF. Definite or probable HF required HF symptoms, such as shortness of breath or oedema. In addition to symptoms, classification of probable HF required diagnosis of HF by a physician and a receipt for medical treatment for HF. Definite HF also required one or more objective criteria, such as pulmonary oedema/congestion by chest X-ray; dilated ventricle or poor LV function by echocardiography or ventriculography; or evidence of LV diastolic dysfunction.^{14 (link)} For this analysis, we used incident definite or probable HF as a single entity without subdividing it into systolic or diastolic predominance.

Chahal H., Bluemke D.A., Wu C.O., McClelland R., Liu K., Shea S.J., Burke G., Balfour P., Herrington D., Shi P., Post W., Olson J., Watson K.E., Folsom A.R, & Lima J.A. (2014). Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis. Heart (British Cardiac Society), 101(1), 58-64.

Publication 2014

Cardiologists Cardiovascular System Cerebral Ventriculography Diagnosis Diastole Dyspnea Echocardiography Edema Epidemiologists Heart Ventricle Hospitalization Interviewers Left Ventricular Diastolic Dysfunction Outpatients Physical Examination Physicians Pulmonary Edema Radiography, Thoracic Systole

Most recents protocols related to «Left Ventricular Diastolic Dysfunction»

Sepsis-Induced Cardiac Dysfunction in Adults

Between November 2020 and March 2022, adults who had been admitted to the emergency department of Hunan Provincial People’s Hospital were selected for the study. Patients with sepsis were included in the study within the first 24 hours after admission. The inclusion criteria of patients were based on Sepsis 3.0 in the Third International Consensus Conference. Sepsis was defined as life-threatening organ dysfunction induced by a dysregulated host response to infection and a Sequential Organ Failure Assessment (SOFA) score ≥ 2 (15 (link)). Sepsis-induced cardiac dysfunction was defined as impaired but reversible cardiac dysfunction under echocardiography, including LV systolic dysfunction, LV diastolic dysfunction, and right ventricle (RV) systolic dysfunction (16 (link)). Patients who met the exclusion criteria were as follows: (1) age < 18 years old; (2) pregnancy; and (3) history of heart disease, such as acute coronary ischaemia, LV insufficiency, dilated cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, or recurrent arrhythmia (5 (link)). The study complied with the guidelines of the Declaration of Helsinki and the Conference for Coordination of Clinical Practice and was approved by the Ethics Committee of Hunan Provincial People’s Hospital. Informed consent was obtained from all participants.

Cao Y., Liu Z., Ma W., Fang C., Pei Y., Jing Y., Huang J., Han X, & Xiao W. (2023). Untargeted metabolomic profiling of sepsis-induced cardiac dysfunction. Frontiers in Endocrinology, 14, 1060470.

Full text: Click here

Publication 2023

Adult Cardiac Arrhythmia Cardiomyopathy, Dilated Conferences Echocardiography Emergencies Ethics Committees, Clinical Heart Diseases Heart Failure Hypertrophic Cardiomyopathy Infection Left Ventricular Diastolic Dysfunction Left Ventricular Systolic Dysfunction Myocardial Ischemia Patients Pregnancy Response, Immune Right Ventricular Dysfunction Septicemia Systole Valve Disease, Heart

Left Atrial Access Screening Protocol

We screened a population who needed LA access as a part of a therapeutic procedure for AF or supraventricular tachycardia (Figure 1). From July 2015 to November 2016, 264 patients with AF were enrolled. The control group consisted of 35 patients with re-entry tachycardia via a left-side accessory pathway or left-origin atrial tachycardia. Patients with (1) previous cardiac surgery or procedure history (n = 0), (2) LV systolic dysfunction (LVEF < 50%) or structural heart disease including ischemic lesion (n = 15), (3) moderate to severe mitral and aortic valve disease (n = 0), (4) recurrent triggers, that induced sustained arrhythmias interrupting the maintain sinus rhythm (SR) (n = 1), and (5) AF induction during right atrial pacing (n = 14 in AF group and n = 1 in control group) were excluded via a screening test. A total of 204 patients in the AF group and 34 patients in the control group were finally analyzed (male 77.1%, 54.0 ± 12.4 years old). In addition, the cohort was divided into two groups based on the criteria of E/e’ = 8 (median value), which is an echocardiographic LV diastolic dysfunction marker. We compared 144 patients with low E/e’ and 124 patients with high E/e’. All patients provided written informed consent for inclusion in the cohort. The research protocol complied with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the Korea University Anam Hospital.

Roh S.Y., Lee D.I., Lee K.N., Ahn J., Baek Y.S., Kim D.H., Shim J., Choi J.I, & Kim Y.H. (2023). E/e’ Ratio Predicts the Atrial Pacing-Induced Left Atrial Pressure Response in Patients with Preserved Ejection Fraction. Medicina, 59(2), 210.

Full text: Click here

Publication 2023

A 204 AF 14 Atrium, Left Atrium, Right Birth Bundles, Accessory Atrioventricular Cardiac Arrhythmia Echocardiography Ethics Committees, Research Heart Diseases Left Ventricular Diastolic Dysfunction Left Ventricular Systolic Dysfunction Males Patients Precipitating Factors Sinuses, Nasal Supraventricular Tachycardia Surgical Procedure, Cardiac Therapeutics Valve Disorder, Aortic

HFpEF Subgroups and CVD Risk Factors

A total of 33 patients diagnosed with HFpEF were enrolled in this study, according to the latest guidelines for HF [16 (link)]. Transthoracic echocardiography was performed and blood samples were collected from each participant at the time of the outpatient visit or hospital admission. Patients were excluded if there was a presence of significant valvular disease. Patients were divided into three sub-groups of HFpEF depending on their clinical symptoms: HCM (n = 15), acute HFpEF (n = 9) and chronic HFpEF (n = 9). A control group (n = 40) of participants who were high-risk for CVD, but without left ventricular diastolic dysfunction, were also included in this study (Table 1).
All participants provided written consent prior to inclusion and blood collection. This study was conducted in accordance with the Declaration of Helsinki and ethical approval was obtained from individual hospitals and institutions.

Chhor M., Chen H., Jerotić D., Tešić M., Nikolić V.N., Pavlović M., Vučić R.M., Rayner B., Watson C.J., Ledwidge M., McDonald K., Robson T., McGrath K.C, & McClements L. (2023). FK506-Binding Protein like (FKBPL) Has an Important Role in Heart Failure with Preserved Ejection Fraction Pathogenesis with Potential Diagnostic Utility. Biomolecules, 13(2), 395.

Full text: Click here

Publication 2023

BLOOD Echocardiography Left Ventricular Diastolic Dysfunction Outpatients Patients

Evaluating Left Atrial Remodeling

In this study, 3 indices were calculated to evaluate LA structure remodeling, including LA volume index, LA sphericity index, and LA reverse remodeling (LARR). LA volume index, measured by 2‐dimensional echocardiography, is an accurate descriptor of LA volume and could reflect LV diastolic dysfunction.⁹ LA sphericity index is a novel index to assess the agreement between LA shape and a perfect sphere, which is more sensitive and changes earlier than LA volume index when exposed to varying stressors.¹⁰ It can be obtained by calculating the ratio of the transverse and longitudinal diameters of the left atrium. LARR is defined as a reduction >15% in the LA end‐systolic volume.¹¹ Other relevant indicators, such as LA diameter, LA transverse diameter, LA superior–inferior diameter, and LA volume were also recorded.

Sun Y., Chen X., Zhang Y., Yu Y., Zhang X., Si J., Ding Z., Xia Y., Tse G, & Liu Y. (2023). Reverse Atrial Remodeling in Heart Failure With Recovered Ejection Fraction. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 12(2), e026891.

Publication 2023

2D Echocardiography Atrium, Left Left Ventricular Diastolic Dysfunction Systole

Left Atrial Strain Analysis in COVID-19 Patients

Left atrial longitudinal strain analysis was obtained using automated speckle tracking software. The regions of interest (ROI) were generated automatically and LA endocardial border was manually adjusted when required.
LA phases definition and LAS values were measured from the LA longitudinal strain curve according to the European Association of Cardiovascular Imaging (EACVI)/American society of echocardiography (ASE) guidelines [5 ].
LAS analysis was calculated with the reference point set at the onset of the QRS complex of the superimposed ECG, two longitudinal deformation parameters are identified, positive peak atrial longitudinal strain at the end of the reservoir phase and a negative peak atrial contraction strain, before atrial contraction [6 (link)]. (Fig. 1.
Fig. 2

ROC curve: Predictors of LV diastolic dysfunction post COVID-19

LA strain rate was measured during the early ventricular filling phase. LA stiffness was calculated as the ratio of E/eʹ to LA reservoir strain x100 [7 (link)].
Global LV systolic strain (GLS) was evaluated, and the software automatically traced the contour of the endocardium at apical three, four and two-chamber views. 2D GLS was analysed during aortic valve closure.

ZeinElabdeen S.G., Sherif A., Kandil N.T., Altabib A.M, & abdelrashid M.A. (2023). Left atrial longitudinal strain analysis in long Covid-19 syndrome. The International Journal of Cardiovascular Imaging, 39(5), 939-944.

Full text: Click here

Publication 2023

Atrium, Left Cardiovascular System Echocardiography Endocardium Europeans Heart Atrium Heart Ventricle Left Ventricular Diastolic Dysfunction Strains Systole Valves, Aortic

Top products related to «Left Ventricular Diastolic Dysfunction»

Vivid 7 by GE Healthcare

Sourced in United States, Norway, United Kingdom, Japan, France, Canada, Germany, Belgium

The Vivid 7 is a high-performance ultrasound system designed for cardiovascular and general imaging applications. It features advanced imaging technologies and versatile capabilities to support comprehensive diagnostic assessments.

Vivid e9 by GE Healthcare

Sourced in United States, Norway, Japan, United Kingdom, Germany

The Vivid E9 is a diagnostic ultrasound system developed by GE Healthcare. It is designed to provide high-quality imaging for a wide range of clinical applications.

Vivid 9 by GE Healthcare

Sourced in Norway, United States, United Kingdom, Japan

The Vivid 9 is a diagnostic ultrasound system designed for cardiac and vascular imaging. It offers high-resolution imaging capabilities and advanced features for healthcare professionals.

Echopac by GE Healthcare

Sourced in Norway, United States, United Kingdom

EchoPAC is a software application developed by GE Healthcare for the analysis and visualization of echocardiographic images. It provides tools for cardiac image management, measurement, and reporting.

Matrix ie33 by Philips

Sourced in United States

The Matrix iE33 is a medical imaging system designed for diagnostic echocardiography. It provides detailed visual information about the structure and function of the heart using advanced ultrasound technology.

Vivid e95 by GE Healthcare

Sourced in United States, Norway, United Kingdom, Japan

The Vivid E95 is a high-performance cardiovascular ultrasound system designed for comprehensive cardiac and vascular imaging. It features advanced technologies and a user-friendly interface.

Spss version 18 by IBM

Sourced in United States, United Kingdom, Japan, Thailand, China, Italy, Germany

SPSS version 18.0 is a statistical software package developed by IBM. It provides data management, analysis, and reporting capabilities. The core function of SPSS is to assist in the analysis of data and presentation of results.

Echopac software by GE Healthcare

Sourced in United States, Norway

EchoPAC is a software application developed by GE Healthcare that is designed to analyze and interpret echocardiographic data. The software provides tools for visualizing, measuring, and quantifying cardiac structures and functions from echocardiographic images and data.

Sas statistical software by SAS Institute

Sourced in United States, Austria, Japan, Cameroon

SAS statistical software is a comprehensive data analysis and visualization tool. It provides a wide range of statistical procedures and analytical capabilities for managing, analyzing, and presenting data. The software is designed to handle large and complex datasets, allowing users to perform advanced statistical modeling, regression analysis, and data mining tasks. The core function of the SAS statistical software is to enable users to extract insights and make data-driven decisions.

Jmp 8 by SAS Institute

Sourced in United States, Japan

JMP 8.0 is a statistical discovery software package developed by SAS Institute. It provides data analysis, visualization, and modeling capabilities. The software is designed for scientific and engineering applications.

What is Left Ventricular Diastolic Dysfunction?

What are the different types of Left Ventricular Diastolic Dysfunction?

How can PubCompare.ai help with researching Left Ventricular Diastolic Dysfunction?

PubCompare.ai allows you to screen protocol literature more efficiently and leverage AI to pinpoint critical insights. The platform can help researchers identify the most effective protocols related to Left Ventricular Diastolic Dysfunction for their specific research goals. The AI-driven analysis can highlight key differences in protocol effectiveness, enabling you to choose the best option for reproducibility and accuarcy.

What are some common challenges in using protocols for Left Ventricular Diastolic Dysfunction research?

One of the main challenges in Left Ventricular Diastolic Dysfunction research is the wide range of protocols and variations in methodology across different studies. This can make it difficult to compare results and identify the most effective approaches. PubCompare.ai can help overcome this by providing intelligent comparisons and highlighting the critical differences between protocols, allowing researchers to make more informed decisions.

How can PubCompare.ai assist in optimizing Left Ventricular Diastolic Dysfunction research?

PubCompare.ai's AI-driven platform can help researchers streamline their work on Left Ventricular Diastolic Dysfunction by locating the best protocols from literature, pre-prinks, and patents, while using intelligent comparisons to enhance reproducibility and accuarcy. This can save time, improve the quality of research, and increase the chances of uncovering the most effective solutions for managing LVDD.

More about "Left Ventricular Diastolic Dysfunction"

Left Ventricular Diastolic Dysfunction (LVDD) is a condition where the left ventricle of the heart has impaired ability to relax and fill with blood during the diastolic phase of the cardiac cycle.
This can lead to symptoms such as shortness of breath, fatigue, and edema.
LVDD is often associated with other cardiovascular conditions like hypertension, coronary artery disease, and heart failure.
PubCompare.ai is an AI-driven platform that can help researchers optimize their studies on LVDD.
The platform can locate the best protocols from literature, pre-prints, and patents, and use intelligent comparisons to enhance the reproducibility and accuracy of research.
Researchers can leverage the power of AI to streamline their LVDD studies and uncover the most effective solutions.
In addition to the PubCompare.ai platform, researchers may also utilize various echocardiography systems, such as Vivid 7, Vivid E9, Vivid 9, EchoPAC, Matrix iE33, and Vivid E95, to assess and diagnose LVDD.
These systems provide advanced imaging capabilities and quantitative analysis tools that can help clinicians and researchers better understand the underlying mechanisms and characteristics of LVDD.
Furthermore, researchers may employ statistical software like SPSS version 18.0, SAS statistical software, and JMP 8.0 to analyze the data collected from their LVDD studies.
These tools can help researchers identify patterns, trends, and relationships within the data, and draw meaningful conclusions to inform their research and treatment strategies.
By harnessing the power of AI, advanced imaging technologies, and robust statistical analysis, researchers can optimize their investigations into Left Ventricular Diastolic Dysfunction and uncover the most effective solutions to improve patient outcomes.